New advances in the research of clinical treatment and novel anticancer agents in tumor angiogenesis.

[1]  Huili Yuan,et al.  A powerful antitumor "trident": the combination of radio-, immuno- and anti-angiogenesis therapy based on mesoporous silica single coated gold nanoparticles. , 2023, Journal of materials chemistry. B.

[2]  Qun Lv,et al.  Ginsenoside Rg3 alleviates the migration, invasion, and angiogenesis of lung cancer cells by inhibiting the expressions of cyclooxygenase‐2 and vascular endothelial growth factor , 2023, Chemical biology & drug design.

[3]  G. Sethi,et al.  Resveratrol and Its Role in the Management of B-Cell Malignancies—A Recent Update , 2023, Biomedicines.

[4]  Lei Zhou,et al.  Targeting OPA1-Mediated Mitochondrial Fusion Contributed to Celastrol’s Anti-Tumor Angiogenesis Effect , 2022, Pharmaceutics.

[5]  M. Mandal,et al.  Resveratrol Nanoparticle attenuates metastasis and angiogenesis by deregulating inflammatory cytokines through inhibition of CAFs in oral cancer by CXCL-12/IL-6 dependent pathway. , 2022, The Journal of nutritional biochemistry.

[6]  Feng Xu,et al.  TGF-β1 promotes human breast cancer angiogenesis and malignant behavior by regulating endothelial-mesenchymal transition , 2022, Frontiers in Oncology.

[7]  M. Kumar,et al.  Luteolin, a Potent Anticancer Compound: From Chemistry to Cellular Interactions and Synergetic Perspectives , 2022, Cancers.

[8]  Ajmal Ahmad,et al.  Molecular mechanism of VEGF and its role in pathological angiogenesis , 2022, Journal of cellular biochemistry.

[9]  J. Tímár,et al.  On-Target Side Effects of Targeted Therapeutics of Cancer , 2022, Pathology & Oncology Research.

[10]  X. Dai,et al.  Nanotechnology meets glioblastoma multiforme: Emerging therapeutic strategies. , 2022, Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology.

[11]  Jie Deng,et al.  CXCL5: A coachman to drive cancer progression , 2022, Frontiers in Oncology.

[12]  N. Sattarahmady,et al.  Simultaneous chemotherapy/sonodynamic therapy of the melanoma cancer cells using a gold-paclitaxel nanostructure. , 2022, Photodiagnosis and photodynamic therapy.

[13]  Tong Li,et al.  Bioinspired and Biomimetic Nanomedicines for Targeted Cancer Therapy , 2022, Pharmaceutics.

[14]  J. Ai,et al.  The anti-angiogenic effect of atorvastatin loaded exosomes on glioblastoma tumor cells: An in vitro 3D culture model. , 2022, Microvascular research.

[15]  R. Coriat,et al.  Therapeutic Management of Advanced Hepatocellular Carcinoma: An Updated Review , 2022, Cancers.

[16]  Xi Zhang,et al.  Intelligent porphyrin nano-delivery system for photostimulated and targeted inhibition of angiogenesis. , 2022, International journal of pharmaceutics.

[17]  Xiang Gao,et al.  Research Progress of Natural Product-based Nanomaterials for the Treatment of Inflammation-Related Diseases , 2022, Materials & Design.

[18]  Jie Chen,et al.  The Efficacy of Adjuvant Targeted Therapy in Patients with Advanced Renal Cell Carcinoma: A Systematic Review and Meta-Analysis , 2022, Computational and mathematical methods in medicine.

[19]  Lina Zhang,et al.  Baohuoside I Inhibits Tumor Angiogenesis in Multiple Myeloma via the Peroxisome Proliferator–Activated Receptor γ/Vascular Endothelial Growth Factor Signaling Pathway , 2022, Frontiers in Pharmacology.

[20]  A. Mangoni,et al.  Nano-targeting Vascular Remodelling in Cancer: Recent Developments and Future Directions. , 2022, Seminars in cancer biology.

[21]  Nicholas D. Camarda,et al.  VEGF Receptor Inhibitor-Induced Hypertension: Emerging Mechanisms and Clinical Implications , 2022, Current Oncology Reports.

[22]  Jiaying Guo,et al.  PDGF‐BB/PDGFRβ promotes epithelial–mesenchymal transition by affecting PI3K/AKT/mTOR‐driven aerobic glycolysis in Wilms' tumor G401 cells , 2022, Cell biology international.

[23]  J. Griffith,et al.  Exosome-Encased Nucleic Acid Scaffold Chemotherapeutic Agents for Superior Anti-Tumor and Anti-Angiogenesis Activity , 2022, ACS bio & med chem Au.

[24]  K. Yonemori,et al.  Lenvatinib plus Pembrolizumab for Advanced Endometrial Cancer. , 2022, The New England journal of medicine.

[25]  Yaqin Zhang,et al.  The Endoplasmic Reticulum-Stressed Head and Neck Squamous Cell Carcinoma Cells Induced Exosomal miR-424-5p Inhibits Angiogenesis and Migration of Humanumbilical Vein Endothelial Cells Through LAMC1-Mediated Wnt/β-Catenin Signaling Pathway , 2022, Cell transplantation.

[26]  C. Ji,et al.  Targeting the PDGF/PDGFR signaling pathway for cancer therapy: A review. , 2022, International journal of biological macromolecules.

[27]  Xiaochen Wu,et al.  Development of quercetin-loaded PVCL-PVA-PEG micelles and application in inhibiting tumor angiogenesis through the PI3K/Akt/VEGF pathway. , 2022, Toxicology and applied pharmacology.

[28]  Xiaoping Cai,et al.  Luteolin inhibits viability, migration, angiogenesis and invasion of non-small cell lung cancer vascular endothelial cells via miR-133a-3p/purine rich element binding protein B-mediated MAPK and PI3K/Akt signaling pathways. , 2022, Tissue & cell.

[29]  T. Mostafa,et al.  Celecoxib as an adjuvant to chemotherapy for patients with metastatic colorectal cancer , 2022, Saudi medical journal.

[30]  A. Shakouri,et al.  Nanoencapsulation of Hirudo medicinalis proteins in liposomes as a nanocarrier for inhibiting angiogenesis through targeting VEGFA in the Breast cancer cell line (MCF-7) , 2021, BioImpacts : BI.

[31]  P. Kesharwani,et al.  Recent Progress of RGD Modified Liposomes as Multistage Rocket Against Cancer , 2022, Frontiers in Pharmacology.

[32]  Nuannuan Li,et al.  RNA Drug Delivery Using Biogenic Nanovehicles for Cancer Therapy , 2021, Frontiers in Pharmacology.

[33]  Myung Ah Lee,et al.  Efficacy and safety of atezolizumab plus bevacizumab in Korean patients with advanced hepatocellular carcinoma , 2021, Liver international : official journal of the International Association for the Study of the Liver.

[34]  Xinhua Lin,et al.  Recent Research Progress (2015–2021) and Perspectives on the Pharmacological Effects and Mechanisms of Tanshinone IIA , 2021, Frontiers in Pharmacology.

[35]  Jun Zhao,et al.  Camrelizumab plus apatinib in patients with high-risk chemorefractory or relapsed gestational trophoblastic neoplasia (CAP 01): a single-arm, open-label, phase 2 trial. , 2021, The Lancet. Oncology.

[36]  G. Curigliano,et al.  Selective FGFR/FGF pathway inhibitors: inhibition strategies, clinical activities, resistance mutations, and future directions , 2021, Expert review of clinical pharmacology.

[37]  H. Koga,et al.  Lenvatinib versus Sorafenib as first‐line treatment in hepatocellular carcinoma: A multi‐institutional matched case‐control study , 2021, Hepatology research : the official journal of the Japan Society of Hepatology.

[38]  N. Zhong,et al.  Apatinib inhibits the growth of small cell lung cancer via a mechanism mediated by VEGF, PI3K/Akt and Ki‐67/CD31 , 2021, Journal of cellular and molecular medicine.

[39]  K. Ahn,et al.  Crocetin imparts antiproliferative activity via inhibiting STAT3 signaling in hepatocellular carcinoma , 2021, IUBMB life.

[40]  W. Cho,et al.  Colorectal cancer cell-derived extracellular vesicles transfer miR-221-3p to promote endothelial cell angiogenesis via targeting suppressor of cytokine signaling 3. , 2021, Life sciences.

[41]  F. Aires-da-Silva,et al.  Chemokine-Directed Tumor Microenvironment Modulation in Cancer Immunotherapy , 2021, International journal of molecular sciences.

[42]  Muying Ying,et al.  Antitumor Effect of Saikosaponin A on Human Neuroblastoma Cells , 2021, BioMed research international.

[43]  Jianglin Wang,et al.  Crocetin suppresses angiogenesis and metastasis through inhibiting sonic hedgehog signaling pathway in gastric cancer. , 2021, Biochemical and biophysical research communications.

[44]  Yan Zhou,et al.  The Role of the VEGF Family in Coronary Heart Disease , 2021, Frontiers in Cardiovascular Medicine.

[45]  Zhiqiang Sun,et al.  Cost-Effectiveness Analysis of Anlotinib as Third- or Further-Line Treatment for Relapsed Small Cell Lung Cancer (SCLC) in China , 2021, Advances in Therapy.

[46]  Ž. Bajić,et al.  Real-World Efficacy and Safety of Bevacizumab in the First-Line Treatment of Metastatic Cervical Cancer: A Cohort Study in the Total Population of Croatian Patients , 2021, Journal of oncology.

[47]  M. Mak,et al.  Extracellular vesicles as delivery systems at nano-/micro-scale. , 2021, Advanced drug delivery reviews.

[48]  K. Andrabi,et al.  TGF‐β signaling: A recap of SMAD‐independent and SMAD‐dependent pathways , 2021, Journal of cellular physiology.

[49]  E. Hitre,et al.  Cabozantinib for radioiodine-refractory differentiated thyroid cancer (COSMIC-311): a randomised, double-blind, placebo-controlled, phase 3 trial. , 2021, The Lancet. Oncology.

[50]  Yinying Wu,et al.  Apatinib inhibits pancreatic cancer growth, migration and invasion through the PI3K/AKT and ERK1/2/MAPK pathways , 2021, Translational cancer research.

[51]  V. Thongboonkerd,et al.  Epigallocatechin-3-gallate plays more predominant roles than caffeine for inducing actin-crosslinking, ubiquitin/proteasome activity and glycolysis, and suppressing angiogenesis features of human endothelial cells. , 2021, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[52]  Zhuang Liu,et al.  Inorganic nanomaterials with rapid clearance for biomedical applications. , 2021, Chemical Society reviews.

[53]  M. Mokhtari,et al.  Quercetin Can Inhibit Angiogenesis via the Down Regulation of MALAT1 and MIAT LncRNAs in Human Umbilical Vein Endothelial Cells , 2021, International journal of preventive medicine.

[54]  S. Khanum,et al.  Tumor angiogenesis: Current challenges and therapeutic opportunities. , 2021, Cancer treatment and research communications.

[55]  A. Sutton,et al.  miR‐126‐3p is essential for CXCL12‐induced angiogenesis , 2021, Journal of cellular and molecular medicine.

[56]  Chenglei Li,et al.  Dual-Ligand-Modified Liposomes Co-Loaded with Anti-Angiogenic and Chemotherapeutic Drugs for Inhibiting Tumor Angiogenesis and Metastasis , 2021, International journal of nanomedicine.

[57]  Yuting Yin,et al.  Cancer-secreted exosomal miR-21-5p induces angiogenesis and vascular permeability by targeting KRIT1 , 2021, Cell Death & Disease.

[58]  R. Capasso,et al.  Is Emodin with Anticancer Effects Completely Innocent? Two Sides of the Coin , 2021, Cancers.

[59]  Min Suk Shim,et al.  Safe and Targeted Sonodynamic Cancer Therapy Using Biocompatible Exosome-Based Nanosonosensitizers. , 2021, ACS applied materials & interfaces.

[60]  Ying Cheng,et al.  Apatinib as second-line or later therapy in patients with advanced hepatocellular carcinoma (AHELP): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial. , 2021, The lancet. Gastroenterology & hepatology.

[61]  N. Zhang,et al.  Cellular and Molecular Mechanisms of Pristimerin in Cancer Therapy: Recent Advances , 2021, Frontiers in Oncology.

[62]  Yue Liu,et al.  Quercetin inhibits invasion and angiogenesis of esophageal cancer cells. , 2021, Pathology, research and practice.

[63]  Yu Wang,et al.  Recent progress in nanomedicine for enhanced cancer chemotherapy , 2021, Theranostics.

[64]  C. Du,et al.  β-elemene affects angiogenesis of infantile hemangioma by regulating angiotensin-converting enzyme 2 and hypoxia-inducible factor-1 alpha , 2021, Journal of Natural Medicines.

[65]  W. Chao,et al.  Sorafenib combined with dasatinib therapy inhibits cell viability, migration, and angiogenesis synergistically in hepatocellular carcinoma , 2021, Cancer Chemotherapy and Pharmacology.

[66]  K. Mortezaee,et al.  Angiogenesis as a hallmark of solid tumors - clinical perspectives , 2021, Cellular Oncology.

[67]  Yuan Zhang,et al.  Anlotinib in Locally Advanced or Metastatic Medullary Thyroid Carcinoma: A Randomized, Double-Blind Phase IIB Trial , 2021, Clinical Cancer Research.

[68]  Yongli Zhao,et al.  Apatinib suppresses the migration, invasion and angiogenesis of hepatocellular carcinoma cells by blocking VEGF and PI3K/AKT signaling pathways , 2021, Molecular medicine reports.

[69]  P. Kharkar,et al.  Crocetin and related oxygen diffusion‐enhancing compounds: Review of chemical synthesis, pharmacology, clinical development, and novel therapeutic applications , 2021, Drug development research.

[70]  R. Diaz,et al.  The remodelling of actin composition as a hallmark of cancer , 2021, Translational oncology.

[71]  M. Apte,et al.  Angiopoietin inhibitors: A review on targeting tumor angiogenesis. , 2021, European journal of pharmacology.

[72]  D. Aggarwal,et al.  A metabolite that exhibits anti-neoplastic activities by modulating multiple oncogenic targets. , 2021, Toxicology in vitro : an international journal published in association with BIBRA.

[73]  M. Mandal,et al.  Nano formulated Resveratrol inhibits metastasis and angiogenesis by reducing inflammatory cytokines in oral cancer cells by targeting tumor associated macrophages. , 2021, The Journal of nutritional biochemistry.

[74]  Y. Liu,et al.  Camrelizumab in combination with apatinib in second-line or above therapy for advanced primary liver cancer: cohort A report in a multicenter phase Ib/II trial , 2021, Journal for ImmunoTherapy of Cancer.

[75]  Cuizhu Wang,et al.  Insights into the antitumor mechanism of ginsenosides Rg3 , 2021, Molecular Biology Reports.

[76]  A. Khan,et al.  A sonosensitiser‐based polymeric nanoplatform for chemo‐sonodynamic combination therapy of lung cancer , 2021, Journal of Nanobiotechnology.

[77]  M. Parmar,et al.  Cediranib in addition to chemotherapy for women with relapsed platinum-sensitive ovarian cancer (ICON6): overall survival results of a phase III randomised trial , 2021, ESMO open.

[78]  C. Porta,et al.  Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma. , 2021, The New England journal of medicine.

[79]  F. Sheikh,et al.  Anticancer activity of the plant flavonoid luteolin against preclinical models of various cancers and insights on different signalling mechanisms modulated , 2021, Phytotherapy research : PTR.

[80]  Jian-Ying Zhou,et al.  Fruquintinib with gefitinib as first-line therapy in patients carrying EGFR mutations with advanced non-small cell lung cancer: a single-arm, phase II study , 2021, Translational lung cancer research.

[81]  T. George,et al.  Activity of Sorafenib plus Capecitabine (SorCape) in Previously Treated Metastatic Colorectal Cancer. , 2021, The oncologist.

[82]  M. Sangha,et al.  Understanding angiogenesis and the role of angiogenic growth factors in the vascularisation of engineered tissues , 2021, Molecular Biology Reports.

[83]  Youlu Chen,et al.  ROS-responsive capsules engineered from EGCG-Zinc networks improve therapeutic angiogenesis in mouse limb ischemia , 2020, Bioactive materials.

[84]  C. Walko,et al.  Regorafenib , 2013, Reactions Weekly.

[85]  P. Yi,et al.  The Efficacy of Ginsenoside Rg3 Combined with First-line Chemotherapy in the Treatment of Advanced Non-Small Cell Lung Cancer in China: A Systematic Review and Meta-Analysis of Randomized Clinical Trials , 2021, Frontiers in Pharmacology.

[86]  Ying Cheng,et al.  Subgroup analysis by prior anti-VEGF or anti-EGFR target therapy in FRESCO, a randomized, double-blind, Phase III tri1al. , 2020, Future oncology.

[87]  Ying Cheng,et al.  Efficacy and Biomarker Analysis of Camrelizumab in Combination with Apatinib in Patients with Advanced Nonsquamous NSCLC Previously Treated with Chemotherapy , 2020, Clinical Cancer Research.

[88]  Sang Wun Kim,et al.  Use of bevacizumab before or after radiotherapy increases the risk of fistula formation in patients with cervical cancer , 2020, International Journal of Gynecological Cancer.

[89]  Weiguo Tang,et al.  LncRNA MYLK-AS1 facilitates tumor progression and angiogenesis by targeting miR-424-5p/E2F7 axis and activating VEGFR-2 signaling pathway in hepatocellular carcinoma , 2020, Journal of Experimental & Clinical Cancer Research.

[90]  I. Baranowska-Bosiacka,et al.  CC Chemokines in a Tumor: A Review of Pro-Cancer and Anti-Cancer Properties of the Ligands of Receptors CCR1, CCR2, CCR3, and CCR4 , 2020, International journal of molecular sciences.

[91]  V. Vaira,et al.  MiR-126-3p contributes to parathyroid tumor angiogenesis. , 2020, Endocrine-related cancer.

[92]  Tae Won Kim,et al.  Effectiveness of Combining Bevacizumab With First-Line Chemotherapy Regimens for Metastatic Colorectal Cancer in Real-World Practice. , 2020, Clinical colorectal cancer.

[93]  G. Yue,et al.  Tanshinone IIA suppresses ovarian cancer growth through inhibiting malignant properties and angiogenesis , 2020, Annals of translational medicine.

[94]  I. Baranowska-Bosiacka,et al.  CC Chemokines in a Tumor: A Review of Pro-Cancer and Anti-Cancer Properties of Receptors CCR5, CCR6, CCR7, CCR8, CCR9, and CCR10 Ligands , 2020, International journal of molecular sciences.

[95]  Z. Zeng,et al.  The role of microenvironment in tumor angiogenesis , 2020, Journal of experimental & clinical cancer research : CR.

[96]  V. Heinemann,et al.  Nintedanib plus mFOLFOX6 as second‐line treatment of metastatic, chemorefractory colorectal cancer: The randomised, placebo‐controlled, phase II TRICC‐C study (AIO‐KRK‐0111) , 2020, International journal of cancer.

[97]  A. Qadir,et al.  Synergistic effect of bevacizumab and celecoxib on angiogenesis in vitro using human umbilical vein endothelial cells. , 2020, International journal of clinical pharmacology and therapeutics.

[98]  M. Darvish,et al.  The therapeutic potential of resveratrol in a mouse model of melanoma lung metastasis. , 2020, International immunopharmacology.

[99]  E. Bargagli,et al.  Common molecular pathways targeted by Nintedanib in cancer and IPF: a bioinformatic study. , 2020, Pulmonary pharmacology & therapeutics.

[100]  Spencer B. Mamer,et al.  VEGF-A splice variants bind VEGFRs with differential affinities , 2020, Scientific Reports.

[101]  Jian Q. Feng,et al.  FGF/FGFR signaling in health and disease , 2020, Signal Transduction and Targeted Therapy.

[102]  H. Khan,et al.  Kaempferol as a Dietary Anti-Inflammatory Agent: Current Therapeutic Standing , 2020, Molecules.

[103]  W. Teng,et al.  Beta-elemene inhibits differentiated thyroid carcinoma metastasis by reducing cellular proliferation, metabolism and invasion ability , 2020, Annals of translational medicine.

[104]  S. Makuch,et al.  Obligate and facultative anaerobic bacteria in targeted cancer therapy: Current strategies and clinical applications. , 2020, Life sciences.

[105]  Fei Gong,et al.  Newly developed strategies for improving sonodynamic therapy , 2020 .

[106]  Yolanda García García,et al.  Anti-angiogenic therapy for ovarian cancer , 2020, EJC supplements : EJC : official journal of EORTC, European Organization for Research and Treatment of Cancer ... [et al.].

[107]  Yi-chun Chen,et al.  Real-World Study of Adding Bevacizumab to Chemotherapy for Ovarian, Tubal, and Peritoneal Cancer as Front-Line or Relapse Therapy (ROBOT): 8-Year Experience , 2020, Frontiers in Oncology.

[108]  H. Chung,et al.  Cyperenoic acid, a sesquiterpene derivative from Croton crassifolius, inhibits tumor growth through anti-angiogenesis by attenuating VEGFR2 signal pathway in breast cancer. , 2020, Phytomedicine : international journal of phytotherapy and phytopharmacology.

[109]  A. Bishayee,et al.  Molecular mechanisms of action of epigallocatechin gallate in cancer: Recent trends and advancement. , 2020, Seminars in cancer biology.

[110]  Longlong Wang,et al.  Herb-sourced emodin inhibits angiogenesis of breast cancer by targeting VEGFA transcription , 2020, Theranostics.

[111]  S. Thayer,et al.  Hedgehog signaling promotes angiogenesis directly and indirectly in pancreatic cancer , 2020, Angiogenesis.

[112]  Xujiang Chen,et al.  miR-18a-5p Promotes Proliferation and Migration of Vascular Smooth Muscle Cells by Activating the AKT/Extracellular Regulated Protein Kinases (ERK) Signaling Pathway , 2020, Medical science monitor : international medical journal of experimental and clinical research.

[113]  H. Yao,et al.  Efficacy and safety of camrelizumab combined with apatinib in advanced triple-negative breast cancer: an open-label phase II trial , 2020, Journal for immunotherapy of cancer.

[114]  T. Dong,et al.  Kaempferol, a Major Flavonoid in Ginkgo Folium, Potentiates Angiogenic Functions in Cultured Endothelial Cells by Binding to Vascular Endothelial Growth Factor , 2020, Frontiers in Pharmacology.

[115]  Shin A. Yoon,et al.  Multifunctional sonosensitizers in sonodynamic cancer therapy. , 2020, Chemical Society reviews.

[116]  T. Kusakabe,et al.  Distinct Characteristics of VEGF‐D and VEGF‐C to Predict Mortality in Patients With Suspected or Known Coronary Artery Disease , 2020, Journal of the American Heart Association.

[117]  Yan-yan Chen,et al.  The epigallocatechin gallate derivative Y6 inhibits human hepatocellular carcinoma by inhibiting angiogenesis in MAPK/ERK1/2 and PI3K/AKT/ HIF-1α/VEGF dependent pathways. , 2020, Journal of ethnopharmacology.

[118]  M. Birrer,et al.  Ofranergene obadenovec (VB-111) in platinum-resistant ovarian cancer; favorable response rates in a phase I/II study are associated with an immunotherapeutic effect. , 2020, Gynecologic oncology.

[119]  Jijun Fu,et al.  Identification of a novel tumor angiogenesis inhibitor targeting Shh/Gli1 signaling pathway in Non-small cell lung cancer , 2020, Cell Death & Disease.

[120]  B. Sreedhar,et al.  Anti-angiogenic vanadium pentoxide nanoparticles for the treatment of melanoma and their in vivo toxicity study. , 2020, Nanoscale.

[121]  E. Taheri,et al.  Axial Pharmaceutical Properties of Liposome in Cancer Therapy: Recent Advances and Perspectives. , 2020, International journal of pharmaceutics.

[122]  E. Gallo,et al.  Epidermal growth factor receptor (EGFR) involvement in epithelial‐derived cancers and its current antibody‐based immunotherapies , 2020, Cell biology international.

[123]  S. Mousa,et al.  Resveratrol and Its Nanoformulation Attenuate Growth and the Angiogenesis of Xenograft and Orthotopic Colon Cancer Models , 2020, Molecules.

[124]  P. Wei,et al.  A systematical comparison of anti-angiogenesis and anti-cancer efficacy of ramucirumab, apatinib, regorafenib and cabozantinib in zebrafish model. , 2020, Life sciences.

[125]  Wei Gao,et al.  Celastrol Suppresses Glioma Vasculogenic Mimicry Formation and Angiogenesis by Blocking the PI3K/Akt/mTOR Signaling Pathway , 2020, Frontiers in Pharmacology.

[126]  Feng Xie,et al.  Synergistic effects of bevacizumab in combination with β-elemene on subcutaneous xenografts derived from HCT-116 human colon cancer cells , 2020, Translational cancer research.

[127]  Sameh Saber,et al.  Novel complementary antitumour effects of celastrol and metformin by targeting IκBκB, apoptosis and NLRP3 inflammasome activation in diethylnitrosamine-induced murine hepatocarcinogenesis , 2020, Cancer Chemotherapy and Pharmacology.

[128]  L. McGregor,et al.  A phase 1 trial of everolimus and bevacizumab in children with recurrent solid tumors , 2020, Cancer.

[129]  Wei Hou,et al.  Celastrol: Progresses in structure-modifications, structure-activity relationships, pharmacology and toxicology. , 2020, European journal of medicinal chemistry.

[130]  Jeong Ah Kim,et al.  Exosome-mediated microRNA-497 delivery for anti-cancer therapy in a microfluidic 3D lung cancer model. , 2020, Lab on a chip.

[131]  J. Blay,et al.  A double-blind placebo-controlled randomized phase II trial assessing the activity and safety of regorafenib in non-adipocytic patients previously treated with both chemotherapy and pazopanib. , 2020, European journal of cancer.

[132]  Jingguo Li,et al.  Effectively suppressed angiogenesis-mediated retinoblastoma growth using celastrol nanomicelles , 2020, Drug delivery.

[133]  Zhifu Sun,et al.  Spectrum of EGFR aberrations and potential clinical implications: insights from integrative pan‐cancer analysis , 2020, Cancer communications.

[134]  Anubhab Mukherjee,et al.  Recent Advancements of Nanomedicine towards Antiangiogenic Therapy in Cancer , 2020, International journal of molecular sciences.

[135]  Yu Pan,et al.  The microenvironmental and metabolic aspects of sorafenib resistance in hepatocellular carcinoma , 2020, EBioMedicine.

[136]  Everolimus , 2020, Reactions Weekly.

[137]  P. Wen,et al.  Safety and efficacy of VB-111, an anticancer gene therapy, in patients with recurrent glioblastoma: results of a phase I/II study , 2019, Neuro-oncology.

[138]  C. Porta,et al.  Tivozanib versus sorafenib in patients with advanced renal cell carcinoma (TIVO-3): a phase 3, multicentre, randomised, controlled, open-label study. , 2019, The Lancet. Oncology.

[139]  A. Poggi,et al.  Multifocal Signal Modulation Therapy by Celecoxib: A Strategy for Managing Castration-Resistant Prostate Cancer , 2019, International journal of molecular sciences.

[140]  Zhihui Zhu,et al.  Picroside II, an iridoid glycoside from Picrorhiza kurroa, suppresses tumor migration, invasion, and angiogenesis in vitro and in vivo. , 2019, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[141]  M. Sheu,et al.  Epigallocatechin-3-gallate inhibits tumor angiogenesis: involvement of endoglin/Smad1 signaling in human umbilical vein endothelium cells. , 2019, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[142]  Zhejie Chen,et al.  Dietary compound glycyrrhetinic acid suppresses tumor angiogenesis and growth by modulating antiangiogenic and proapoptotic pathways in vitro and in vivo. , 2019, The Journal of nutritional biochemistry.

[143]  A. Dimberg,et al.  Tumor angiogenesis: causes, consequences, challenges and opportunities , 2019, Cellular and Molecular Life Sciences.

[144]  Susheel Kumar Nethi,et al.  Recent Development of Metal Nanoparticles for Angiogenesis Study and Their Therapeutic Applications. , 2019, ACS applied bio materials.

[145]  J. Woillard,et al.  Therapeutic drug monitoring of Everolimus in oncology: evidences and perspectives. , 2019, Therapeutic drug monitoring.

[146]  M. Rahat.  Targeting Angiogenesis With Peptide Vaccines , 2019, Front. Immunol..

[147]  S. Czerczak,et al.  Are platinum nanoparticles safe to human health? , 2019, Medycyna pracy.

[148]  P. Mirmiran,et al.  The effect of saffron on weight and lipid profile: A systematic review, meta‐analysis, and dose–response of randomized clinical trials , 2019, Phytotherapy research : PTR.

[149]  I. Judson,et al.  Cediranib in patients with alveolar soft-part sarcoma (CASPS): a double-blind, placebo-controlled, randomised, phase 2 trial , 2019, The Lancet. Oncology.

[150]  R. Bei,et al.  Multifaceted Role of the Placental Growth Factor (PlGF) in the Antitumor Immune Response and Cancer Progression , 2019, International journal of molecular sciences.

[151]  Ting Duan,et al.  Molecular targets of β-elemene, a herbal extract used in traditional Chinese medicine, and its potential role in cancer therapy: A review. , 2019, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[152]  F. Liao,et al.  Glioma stem cells-derived exosomal miR-26a promotes angiogenesis of microvessel endothelial cells in glioma , 2019, Journal of experimental & clinical cancer research : CR.

[153]  A. Foroughmand,et al.  Combination of Epigallocatechin-3-gallate and Silibinin: A Novel Approach for Targeting Both Tumor and Endothelial Cells , 2019, ACS omega.

[154]  Jian Sun,et al.  Resveratrol Promotes Diabetic Wound Healing via SIRT1-FOXO1-c-Myc Signaling Pathway-Mediated Angiogenesis , 2019, Front. Pharmacol..

[155]  T. Ebner,et al.  Clinical Pharmacokinetics and Pharmacodynamics of Nintedanib , 2019, Clinical Pharmacokinetics.

[156]  Xiaomin Dong,et al.  Antitumor activity of ginsenoside Rg3 in melanoma through downregulation of the ERK and Akt pathways , 2019, International journal of oncology.

[157]  R. Carlisle,et al.  Novel approaches for the design, delivery and administration of vaccine technologies , 2019, Clinical and experimental immunology.

[158]  Charles R. Thomas,et al.  Integrating nanomedicine into clinical radiotherapy regimens. , 2019, Advanced drug delivery reviews.

[159]  K. Maruyama,et al.  Development of Dendritic Cell-Based Immunotherapy Targeting Tumor Blood Vessels in a Mouse Model of Lung Metastasis. , 2019, Biological & pharmaceutical bulletin.

[160]  R. Bonecchi,et al.  Chemokines and Chemokine Receptors: New Targets for Cancer Immunotherapy , 2019, Front. Immunol..

[161]  Zhongwen Xie,et al.  Epigallocatechin-3-gallate inhibits the growth and increases the apoptosis of human thyroid carcinoma cells through suppression of EGFR/RAS/RAF/MEK/ERK signaling pathway , 2019, Cancer Cell International.

[162]  H. Naderi-manesh,et al.  A cyclic peptide reproducing the α1 helix of VEGF-B binds to VEGFR-1 and VEGFR-2 and inhibits angiogenesis and tumor growth. , 2019, The Biochemical journal.

[163]  G. Giatsidis,et al.  MicroRNA‐135a‐3p regulates angiogenesis and tissue repair by targeting p38 signaling in endothelial cells , 2019, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[164]  T. Dong,et al.  Binding of Resveratrol to Vascular Endothelial Growth Factor Suppresses Angiogenesis by Inhibiting the Receptor Signaling. , 2018, Journal of agricultural and food chemistry.

[165]  G. Camussi,et al.  Extracellular vesicles from human liver stem cells inhibit tumor angiogenesis , 2018, International journal of cancer.

[166]  Y. Yen,et al.  Randomized trial of oral cyclophosphamide versus oral cyclophosphamide with celecoxib for recurrent epithelial ovarian, fallopian tube, and primary peritoneal cancer. , 2019, Cancer treatment and research communications.

[167]  A. Brandes,et al.  Regorafenib compared with lomustine in patients with relapsed glioblastoma (REGOMA): a multicentre, open-label, randomised, controlled, phase 2 trial. , 2019, The Lancet. Oncology.

[168]  J. Blay,et al.  Efficacy and safety of regorafenib in adult patients with metastatic osteosarcoma: a non-comparative, randomised, double-blind, placebo-controlled, phase 2 study. , 2019, The Lancet. Oncology.

[169]  Ying Cheng,et al.  First-line axitinib versus sorafenib in Asian patients with metastatic renal cell carcinoma: exploratory subgroup analyses of Phase III data. , 2019, Future oncology.

[170]  L. Schito.  Bridging angiogenesis and immune evasion in the hypoxic tumor microenvironment. , 2018, American journal of physiology. Regulatory, integrative and comparative physiology.

[171]  Y. Takeda,et al.  Exosomal miR-155 Derived from Hepatocellular Carcinoma Cells Under Hypoxia Promotes Angiogenesis in Endothelial Cells , 2018, Digestive Diseases and Sciences.

[172]  Ying Cheng,et al.  Effect of Anlotinib as a Third-Line or Further Treatment on Overall Survival of Patients With Advanced Non–Small Cell Lung Cancer: The ALTER 0303 Phase 3 Randomized Clinical Trial , 2018, JAMA oncology.

[173]  M. Shirley.  Fruquintinib: First Global Approval , 2018, Drugs.

[174]  N. Lee,et al.  Functions of the CXC ligand family in the pancreatic tumor microenvironment. , 2018, Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.].

[175]  Lin Zhou,et al.  Emodin suppresses angiogenesis and metastasis in anaplastic thyroid cancer by affecting TRAF6‑mediated pathways in vivo and in vitro. , 2018, Molecular medicine reports.

[176]  R. Motzer,et al.  Outcomes based on prior therapy in the phase 3 METEOR trial of cabozantinib versus everolimus in advanced renal cell carcinoma , 2018, British Journal of Cancer.

[177]  Hongyan Wu,et al.  Resveratrol inhibits VEGF‐induced angiogenesis in human endothelial cells associated with suppression of aerobic glycolysis via modulation of PKM2 nuclear translocation , 2018, Clinical and experimental pharmacology & physiology.

[178]  A. Bishayee,et al.  Molecular targets of celastrol in cancer: Recent trends and advancements. , 2018, Critical reviews in oncology/hematology.

[179]  Bin Wang,et al.  Delivery of small interfering RNA against Nogo-B receptor via tumor-acidity responsive nanoparticles for tumor vessel normalization and metastasis suppression. , 2018, Biomaterials.

[180]  E. Van Cutsem,et al.  Nintedanib for the treatment of patients with refractory metastatic colorectal cancer (LUME-Colon 1): a phase III, international, randomized, placebo-controlled study , 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

[181]  Gisela Schwab,et al.  Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma , 2018, The New England journal of medicine.

[182]  Guang-Ji Wang,et al.  Apatinib, a selective VEGFR2 inhibitor, improves the delivery of chemotherapeutic agents to tumors by normalizing tumor vessels in LoVo colon cancer xenograft mice , 2018, Acta Pharmacologica Sinica.

[183]  Minmin Wu,et al.  Luteolin inhibits angiogenesis of the M2‑like TAMs via the downregulation of hypoxia inducible factor‑1α and the STAT3 signalling pathway under hypoxia. , 2018, Molecular medicine reports.

[184]  R. Zulli,et al.  Management of VEGF-Targeted Therapy-Induced Hypertension , 2018, Current Hypertension Reports.

[185]  R. Agarwal,et al.  Nintedanib inhibits growth of human prostate carcinoma cells by modulating both cell cycle and angiogenesis regulators , 2018, Scientific Reports.

[186]  F. Du,et al.  Safety and Efficacy of Anlotinib, a Multikinase Angiogenesis Inhibitor, in Patients with Refractory Metastatic Soft-Tissue Sarcoma , 2018, Clinical Cancer Research.

[187]  Qi Wang,et al.  Oridonin inhibits VEGF-A-associated angiogenesis and epithelial-mesenchymal transition of breast cancer in vitro and in vivo , 2018, Oncology letters.

[188]  R. Verhaak,et al.  EGFR heterogeneity and implications for therapeutic intervention in glioblastoma , 2018, Neuro-oncology.

[189]  S. Adams,et al.  Matrix Metalloproteinase Inhibitors in Cancer Therapy: Turning Past Failures Into Future Successes , 2018, Molecular Cancer Therapeutics.

[190]  A. Czirók,et al.  Nintedanib Is Active in Malignant Pleural Mesothelioma Cell Models and Inhibits Angiogenesis and Tumor Growth In Vivo , 2018, Clinical Cancer Research.

[191]  P. Cottu,et al.  Evaluation at 3 years of concurrent bevacizumab and radiotherapy for breast cancer: Results of a prospective study. , 2018, Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique.

[192]  Jai-Sing Yang,et al.  Kaempferol inhibits angiogenic ability by targeting VEGF receptor-2 and downregulating the PI3K/AKT, MEK and ERK pathways in VEGF-stimulated human umbilical vein endothelial cells. , 2018, Oncology reports.

[193]  R. Nibbs,et al.  A guide to chemokines and their receptors , 2018, The FEBS journal.

[194]  Xi Chen,et al.  MicroRNA-181a promotes angiogenesis in colorectal cancer by targeting SRCIN1 to promote the SRC/VEGF signaling pathway , 2018, Cell Death & Disease.

[195]  M. Zheng,et al.  Preclinical characterization of anlotinib, a highly potent and selective vascular endothelial growth factor receptor‐2 inhibitor , 2018, Cancer science.

[196]  M. Kudo,et al.  Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial , 2018, The Lancet.

[197]  G. Carballo,et al.  A highlight on Sonic hedgehog pathway , 2018, Cell Communication and Signaling.

[198]  Taiguo Liu,et al.  Ginsenoside Rg3 Sensitizes Colorectal Cancer to Radiotherapy through Downregulation of Proliferative and Angiogenic Biomarkers , 2018, Evidence-based complementary and alternative medicine : eCAM.

[199]  Ling Zhou,et al.  Assessment of in vivo anti‐tumor activity of human umbilical vein endothelial cell vaccines prepared by various antigen forms , 2018, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[200]  M. Moradzadeh,et al.  Anti‐tumor effects of crocetin and related molecular targets , 2018, Journal of cellular physiology.

[201]  Shuliang Song,et al.  Advances in studies of tyrosine kinase inhibitors and their acquired resistance , 2018, Molecular Cancer.

[202]  Y. Ba,et al.  Exosomes serve as nanoparticles to suppress tumor growth and angiogenesis in gastric cancer by delivering hepatocyte growth factor siRNA , 2018, Cancer science.

[203]  Y. Liu,et al.  MicroRNA-101 inhibits angiogenesis via COX-2 in endometrial carcinoma , 2018, Molecular and Cellular Biochemistry.

[204]  B. Yousef,et al.  Pristimerin exhibits in vitro and in vivo anticancer activities through inhibition of nuclear factor-кB signaling pathway in colorectal cancer cells. , 2018, Phytomedicine : international journal of phytotherapy and phytopharmacology.

[205]  S. Sigismund,et al.  Emerging functions of the EGFR in cancer , 2017, Molecular oncology.

[206]  Bairong Shen,et al.  Ginsenoside Rg3 targets cancer stem cells and tumor angiogenesis to inhibit colorectal cancer progression in vivo , 2017, International journal of oncology.

[207]  T. Mikkelsen,et al.  Phase II study of cabozantinib in patients with progressive glioblastoma: subset analysis of patients with prior antiangiogenic therapy , 2017, Neuro-oncology.

[208]  C. Werner,et al.  Evaluation of Three-Dimensional in Vitro Models to Study Tumor Angiogenesis. , 2017, ACS biomaterials science & engineering.

[209]  Dong-yan Huang,et al.  Inhibition of EGF expression and NF-κB activity by treatment with quercetin leads to suppression of angiogenesis in nasopharyngeal carcinoma , 2016, Saudi journal of biological sciences.

[210]  C. Grüllich.  Cabozantinib: Multi-kinase Inhibitor of MET, AXL, RET, and VEGFR2. , 2018, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer.

[211]  C. T. Hagan,et al.  Nanotechnology Approaches to Improving Cancer Immunotherapy. , 2018, Advances in cancer research.

[212]  Xiyong Liu,et al.  miR-143-3p targeting of ITGA6 suppresses tumour growth and angiogenesis by downregulating PLGF expression via the PI3K/AKT pathway in gallbladder carcinoma , 2018, Cell Death & Disease.

[213]  Chih-Hsin Tang,et al.  Tanshinone IIA inhibits angiogenesis in human endothelial progenitor cells in vitro and in vivo , 2017, Oncotarget.

[214]  J. Bruix,et al.  Prognostic factors and predictors of sorafenib benefit in patients with hepatocellular carcinoma: Analysis of two phase III studies. , 2017, Journal of hepatology.

[215]  M. Mita,et al.  Oncolytic reovirus inhibits angiogenesis through induction of CXCL10/IP-10 and abrogation of HIF activity in soft tissue sarcomas , 2017, Oncotarget.

[216]  V. Palma,et al.  Sonic hedgehog (SHH) signaling improves the angiogenic potential of Wharton’s jelly-derived mesenchymal stem cells (WJ-MSC) , 2017, Stem Cell Research & Therapy.

[217]  Lijuan Hu,et al.  Emodin and rhein decrease levels of hypoxia-inducible factor-1α in human pancreatic cancer cells and attenuate cancer cachexia in athymic mice carrying these cells , 2017, Oncotarget.

[218]  Chunpu Li,et al.  Tanshinone IIA inhibits β-catenin/VEGF-mediated angiogenesis by targeting TGF-β1 in normoxic and HIF-1α in hypoxic microenvironments in human colorectal cancer. , 2017, Cancer letters.

[219]  Hongyan Wu,et al.  Resveratrol suppresses pulmonary tumor metastasis by inhibiting platelet-mediated angiogenic responses. , 2017, The Journal of surgical research.

[220]  Yue Liu,et al.  Low concentration of quercetin antagonizes the invasion and angiogenesis of human glioblastoma U251 cells , 2017, OncoTargets and therapy.

[221]  W. Ye,et al.  Luteolin inhibits angiogenesis by blocking Gas6/Axl signaling pathway. , 2017, International journal of oncology.

[222]  S. Rey,et al.  Hypoxic pathobiology of breast cancer metastasis. , 2017, Biochimica et biophysica acta. Reviews on cancer.

[223]  A. Poggi,et al.  The ErbB family and androgen receptor signaling are targets of Celecoxib in prostate cancer. , 2017, Cancer letters.

[224]  G. Jiang,et al.  Nano-based delivery of RNAi in cancer therapy , 2017, Molecular Cancer.

[225]  Y. Ba,et al.  miR-26a/b Inhibit Tumor Growth and Angiogenesis by Targeting the HGF-VEGF Axis in Gastric Carcinoma , 2017, Cellular Physiology and Biochemistry.

[226]  Woochul Chang,et al.  Endothelial miR-26a regulates VEGF-Nogo-B receptor-mediated angiogenesis , 2017, BMB reports.

[227]  Yu-Chang Liu,et al.  Regorafenib diminishes the expression and secretion of angiogenesis and metastasis associated proteins and inhibits cell invasion via NF-κB inactivation in SK-Hep1 cells. , 2017, Oncology letters.

[228]  Oh Youn Kim,et al.  Extracellular vesicle mimetics: Novel alternatives to extracellular vesicle-based theranostics, drug delivery, and vaccines. , 2017, Seminars in cell & developmental biology.

[229]  Bruno Larrivée,et al.  Tumor angiogenesis and vascular normalization: alternative therapeutic targets , 2017, Angiogenesis.

[230]  Allan Hackshaw,et al.  Comparison of gefitinib, erlotinib and afatinib in non‐small cell lung cancer: A meta‐analysis , 2017, International journal of cancer.

[231]  Andrius Kazlauskas,et al.  PDGFs and their receptors. , 2017, Gene.

[232]  M. Okada-Hatakeyama,et al.  Current status of mathematical modeling of cancer – From the viewpoint of cancer hallmarks , 2017 .

[233]  K. Okamoto,et al.  Targeting of tumor growth and angiogenesis underlies the enhanced antitumor activity of lenvatinib in combination with everolimus , 2017, Cancer science.

[234]  A. Griffioen,et al.  Anti-angiogenesis for cancer revisited: Is there a role for combinations with immunotherapy? , 2017, Angiogenesis.

[235]  Lei Chen,et al.  New knowledge of the mechanisms of sorafenib resistance in liver cancer , 2017, Acta Pharmacologica Sinica.

[236]  N. Turner,et al.  Advances and challenges in targeting FGFR signalling in cancer , 2017, Nature Reviews Cancer.

[237]  Ying E Zhang,et al.  Non-Smad Signaling Pathways of the TGF-β Family. , 2017, Cold Spring Harbor perspectives in biology.

[238]  S. Punia,et al.  Kaempferol – A dietary anticancer molecule with multiple mechanisms of action: Recent trends and advancements , 2017, Journal of Functional Foods.

[239]  Masatoshi Kudo,et al.  Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial , 2017, The Lancet.

[240]  Xinran Tang,et al.  MicroRNA-101 inhibits invasion and angiogenesis through targeting ITGA3 and its systemic delivery inhibits lung metastasis in nasopharyngeal carcinoma , 2017, Cell Death & Disease.

[241]  F. Chen,et al.  Therapeutic effect of apatinib on overall survival is mediated by prolonged progression-free survival in advanced gastric cancer patients , 2016, Oncotarget.

[242]  A. Ridiandries,et al.  The Role of CC-Chemokines in the Regulation of Angiogenesis. , 2016, International journal of molecular sciences.

[243]  J. Patard,et al.  Adjuvant Sunitinib in High-Risk Renal-Cell Carcinoma after Nephrectomy. , 2016, The New England journal of medicine.

[244]  Robert J. Coffey,et al.  EGF receptor ligands: recent advances , 2016, F1000Research.

[245]  Hyo-Jeong Lee,et al.  Anti-cancer effect of pristimerin by inhibition of HIF-1α involves the SPHK-1 pathway in hypoxic prostate cancer cells , 2016, BMC Cancer.

[246]  Anping Li,et al.  The CXCL8-CXCR1/2 pathways in cancer , 2016, Cytokine & growth factor reviews.

[247]  Yi-tao Ding,et al.  MiR-145 functions as a tumor suppressor via regulating angiopoietin-2 in pancreatic cancer cells , 2016, Cancer Cell International.

[248]  K. Moudgil,et al.  Control of autoimmune inflammation by celastrol, a natural triterpenoid. , 2016, Pathogens and disease.

[249]  Emma Gordon,et al.  Mechanisms and regulation of endothelial VEGF receptor signalling , 2016, Nature Reviews Molecular Cell Biology.

[250]  K. Sak,et al.  Molecular mechanisms of action of quercetin in cancer: recent advances , 2016, Tumor Biology.

[251]  S. Ku,et al.  PEGylated lipid bilayer-supported mesoporous silica nanoparticle composite for synergistic co-delivery of axitinib and celastrol in multi-targeted cancer therapy. , 2016, Acta biomaterialia.

[252]  Jiahuai Han,et al.  MicroRNA-17~92 inhibits colorectal cancer progression by targeting angiogenesis. , 2016, Cancer letters.

[253]  Z. Zou,et al.  Quercetin inhibits angiogenesis by targeting calcineurin in the xenograft model of human breast cancer. , 2016, European journal of pharmacology.

[254]  Ping Wang,et al.  Mesenchymal stem cells generate pericytes to promote tumor recurrence via vasculogenesis after stereotactic body radiation therapy. , 2016, Cancer letters.

[255]  V. Syed,et al.  TGF‐β Signaling in Cancer , 2016, Journal of cellular biochemistry.

[256]  Jian Ni,et al.  Emodin: A Review of its Pharmacology, Toxicity and Pharmacokinetics , 2016, Phytotherapy research : PTR.

[257]  R. Derynck,et al.  TGF-β and the TGF-β Family: Context-Dependent Roles in Cell and Tissue Physiology. , 2016, Cold Spring Harbor perspectives in biology.

[258]  E. Solary,et al.  Gap junction-mediated transfer of miR-145-5p from microvascular endothelial cells to colon cancer cells inhibits angiogenesis , 2016, Oncotarget.

[259]  F. J. Vermolen,et al.  Mathematical modelling of angiogenesis using continuous cell-based models , 2016, Biomechanics and modeling in mechanobiology.

[260]  S. Rosochacki,et al.  Matrix metalloproteinases (MMPs), the main extracellular matrix (ECM) enzymes in collagen degradation, as a target for anticancer drugs , 2016, Journal of enzyme inhibition and medicinal chemistry.

[261]  Y. Liu,et al.  MicroRNA‐185 inhibits angiogenesis in human microvascular endothelial cells through targeting stromal interaction molecule 1 , 2016, Cell biology international.

[262]  Y. E. Chen,et al.  Adipose-Derived Stem Cells Induce Angiogenesis via Microvesicle Transport of miRNA-31 , 2016, Stem cells translational medicine.

[263]  Z. Mei,et al.  Quercetin inhibits angiogenesis through thrombospondin-1 upregulation to antagonize human prostate cancer PC-3 cell growth in vitro and in vivo. , 2016, Oncology reports.

[264]  Yihai Cao,et al.  Resveratrol analogue 4,4′-dihydroxy-trans-stilbene potently inhibits cancer invasion and metastasis , 2016, Scientific Reports.

[265]  R. Wong,et al.  Role of microRNA-520h in 20(R)-ginsenoside-Rg3-mediated angiosuppression , 2015, Journal of ginseng research.

[266]  P. Kantoff,et al.  Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma. , 2015, The New England journal of medicine.

[267]  He-da Zhang,et al.  Luteolin Inhibits Breast Cancer Development and Progression In Vitro and In Vivo by Suppressing Notch Signaling and Regulating MiRNAs , 2015, Cellular Physiology and Biochemistry.

[268]  G. D'andrea.  Quercetin: A flavonol with multifaceted therapeutic applications? , 2015, Fitoterapia.

[269]  S. Mo,et al.  The antitumor effect of tanshinone IIA on anti-proliferation and decreasing VEGF/VEGFR2 expression on the human non-small cell lung cancer A549 cell line , 2015, Acta pharmaceutica Sinica. B.

[270]  N. Jha,et al.  Comparative study of anti-angiogenic activities of luteolin, lectin and lupeol biomolecules , 2015, Journal of Translational Medicine.

[271]  Razelle Kurzrock,et al.  The FGFR Landscape in Cancer: Analysis of 4,853 Tumors by Next-Generation Sequencing , 2015, Clinical Cancer Research.

[272]  A. Sureda,et al.  Kaempferol and inflammation: From chemistry to medicine. , 2015, Pharmacological research.

[273]  K. Syrigos,et al.  Afatinib versus erlotinib as second-line treatment of patients with advanced squamous cell carcinoma of the lung (LUX-Lung 8): an open-label randomised controlled phase 3 trial. , 2015, The Lancet. Oncology.

[274]  P. Hohenberger,et al.  Combined Radiation Therapy and Sunitinib for Preoperative Treatment of Soft Tissue Sarcoma , 2015, Annals of Surgical Oncology.

[275]  Fei Liu,et al.  Epigallocatechin-3-gallate inhibits nicotine-induced migration and invasion by the suppression of angiogenesis and epithelial-mesenchymal transition in non-small cell lung cancer cells. , 2015, Oncology reports.

[276]  Yi-long Wu,et al.  Symptom and Quality of Life Improvement in LUX-Lung 6: An Open-Label Phase III Study of Afatinib Versus Cisplatin/Gemcitabine in Asian Patients With EGFR Mutation-Positive Advanced Non–small-cell Lung Cancer , 2015, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[277]  J. Quigley,et al.  Tumor angiogenesis: MMP-mediated induction of intravasation- and metastasis-sustaining neovasculature. , 2015, Matrix biology : journal of the International Society for Matrix Biology.

[278]  Shan Wang,et al.  The anthraquinone derivative Emodin inhibits angiogenesis and metastasis through downregulating Runx2 activity in breast cancer. , 2015, International journal of oncology.

[279]  T. D. de Gruijl,et al.  Vaccination approach to anti-angiogenic treatment of cancer. , 2015, Biochimica et biophysica acta.

[280]  N. Itoh,et al.  The Fibroblast Growth Factor signaling pathway , 2015, Wiley interdisciplinary reviews. Developmental biology.

[281]  C. Schmidt.  Cediranib aims for a comeback. , 2015, Journal of the National Cancer Institute.

[282]  M. Bollet,et al.  Late toxicities and outcomes of adjuvant radiotherapy combined with concurrent bevacizumab in patients with triple-negative non-metastatic breast cancer. , 2015, The British journal of radiology.

[283]  Sung-Bae Kim,et al.  Lenvatinib versus placebo in radioiodine-refractory thyroid cancer. , 2015, The New England journal of medicine.

[284]  H. Cui,et al.  Tanshinone IIA Inhibits HIF-1α and VEGF Expression in Breast Cancer Cells via mTOR/p70S6K/RPS6/4E-BP1 Signaling Pathway , 2015, PloS one.

[285]  Rolf Kaiser,et al.  Analysis of patient-reported outcomes from the LUME-Lung 1 trial: a randomised, double-blind, placebo-controlled, Phase III study of second-line nintedanib in patients with advanced non-small cell lung cancer. , 2015, European journal of cancer.

[286]  Tao Wang,et al.  MiR-221/222 promote human glioma cell invasion and angiogenesis by targeting TIMP2 , 2015, Tumor Biology.

[287]  Weiguo Qing,et al.  Discovery of fruquintinib, a potent and highly selective small molecule inhibitor of VEGFR 1, 2, 3 tyrosine kinases for cancer therapy , 2014, Cancer biology & therapy.

[288]  S. Fox,et al.  A phase Ib/II translational study of sunitinib with neoadjuvant radiotherapy in soft-tissue sarcoma , 2014, British Journal of Cancer.

[289]  C. Sternberg,et al.  An Open-Label Extension Study to Evaluate Safety and Efficacy of Pazopanib in Patients with Advanced Renal Cell Carcinoma , 2014, Oncology.

[290]  J. Rojas,et al.  Oncolytic vaccinia virus demonstrates antiangiogenic effects mediated by targeting of VEGF , 2014, International journal of cancer.

[291]  C. Fan,et al.  Long-term effects of nanoparticles on nutrition and metabolism. , 2014, Small.

[292]  R. Paschke,et al.  Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial , 2014, The Lancet.

[293]  Yu-guang Liu,et al.  MiR-7-5p is frequently downregulated in glioblastoma microvasculature and inhibits vascular endothelial cell proliferation by targeting RAF1 , 2014, Tumor Biology.

[294]  B. Jiang,et al.  MiR-143 acts as a tumor suppressor by targeting N-RAS and enhances temozolomide-induced apoptosis in glioma , 2014, OncoTarget.

[295]  Q. Ye,et al.  MicroRNA‐26a suppresses angiogenesis in human hepatocellular carcinoma by targeting hepatocyte growth factor‐cMet pathway , 2014, Hepatology.

[296]  Yusuke Nakamura,et al.  A phase I study of combination vaccine treatment of five therapeutic epitope-peptides for metastatic colorectal cancer; safety, immunological response, and clinical outcome , 2014, Journal of Translational Medicine.

[297]  Zhao-You Tang,et al.  MicroRNA-26a Inhibits Angiogenesis by Down-Regulating VEGFA through the PIK3C2α/Akt/HIF-1α Pathway in Hepatocellular Carcinoma , 2013, PloS one.

[298]  M. Kreissl,et al.  Cabozantinib in progressive medullary thyroid cancer. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[299]  Azza B El-Remessy,et al.  Angiogenesis inhibitors in cancer therapy: mechanistic perspective on classification and treatment rationales , 2013, British journal of pharmacology.

[300]  G. Sethi,et al.  Emodin inhibits growth and induces apoptosis in an orthotopic hepatocellular carcinoma model by blocking activation of STAT3 , 2013, British journal of pharmacology.

[301]  J. Reeves,et al.  Pazopanib versus sunitinib in metastatic renal-cell carcinoma. , 2013, The New England journal of medicine.

[302]  Kai-Wei Chang,et al.  MT1-MMP regulates MMP-2 expression and angiogenesis-related functions in human umbilical vein endothelial cells. , 2013, Biochemical and biophysical research communications.

[303]  Jun Shi,et al.  β-Elemene-Attenuated Tumor Angiogenesis by Targeting Notch-1 in Gastric Cancer Stem-Like Cells , 2013, Evidence-based complementary and alternative medicine : eCAM.

[304]  A. Brenner,et al.  Phase I Dose-Escalation Study of VB-111, an Antiangiogenic Virotherapy, in Patients with Advanced Solid Tumors , 2013, Clinical Cancer Research.

[305]  B. Jiang,et al.  MicroRNA-143 inhibits tumor growth and angiogenesis and sensitizes chemosensitivity to oxaliplatin in colorectal cancers , 2013, Cell cycle.

[306]  David Chen,et al.  Everolimus for angiomyolipoma associated with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis (EXIST-2): a multicentre, randomised, double-blind, placebo-controlled trial , 2013, The Lancet.

[307]  J. Buer,et al.  Anti‐infective properties of epigallocatechin‐3‐gallate (EGCG), a component of green tea , 2013, British journal of pharmacology.

[308]  D. Sargent,et al.  Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial , 2013, The Lancet.

[309]  J. Blay,et al.  Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial , 2013, The Lancet.

[310]  E. Thiele,et al.  Efficacy and safety of everolimus for subependymal giant cell astrocytomas associated with tuberous sclerosis complex (EXIST-1): a multicentre, randomised, placebo-controlled phase 3 trial , 2013, The Lancet.

[311]  Kaoru Tanaka,et al.  Phase I trial of OTS11101, an anti‐angiogenic vaccine targeting vascular endothelial growth factor receptor 1 in solid tumor , 2013, Cancer science.

[312]  G. Christofori,et al.  Angiopoietins in angiogenesis. , 2013, Cancer letters.

[313]  Keyuan Zhou,et al.  (−)-Epigallocatechin-3-gallate inhibits human papillomavirus (HPV)-16 oncoprotein-induced angiogenesis in non-small cell lung cancer cells by targeting HIF-1α , 2013, Cancer Chemotherapy and Pharmacology.

[314]  R. Watnick.  The role of the tumor microenvironment in regulating angiogenesis. , 2012, Cold Spring Harbor perspectives in medicine.

[315]  E. Deeks.  Pazopanib , 2012, Drugs.

[316]  C. Klein,et al.  Target Binding Properties and Cellular Activity of Afatinib (BIBW 2992), an Irreversible ErbB Family Blocker , 2012, Journal of Pharmacology and Experimental Therapeutics.

[317]  Kang-jie Chen,et al.  Antitumor Activity of Emodin against Pancreatic Cancer Depends on Its Dual Role: Promotion of Apoptosis and Suppression of Angiogenesis , 2012, PloS one.

[318]  Lixin Sun,et al.  Pristimerin, a Triterpenoid, Inhibits Tumor Angiogenesis by Targeting VEGFR2 Activation , 2012, Molecules.

[319]  J. Blay,et al.  Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial , 2012, The Lancet.

[320]  Y. M. Lee,et al.  Ginsenoside Rg3 attenuates tumor angiogenesis via inhibiting bioactivities of endothelial progenitor cells , 2012, Cancer biology & therapy.

[321]  H. Hara,et al.  Crocetin, a carotenoid derivative, inhibits VEGF-induced angiogenesis via suppression of p38 phosphorylation. , 2012, Current neurovascular research.

[322]  J. Luk,et al.  Celastrol Suppresses Growth and Induces Apoptosis of Human Hepatocellular Carcinoma through the Modulation of STAT3/JAK2 Signaling Cascade In Vitro and In Vivo , 2012, Cancer Prevention Research.

[323]  M. Piccart,et al.  Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. , 2012, The New England journal of medicine.

[324]  Fan Zhang,et al.  Complicated life, complicated VEGF-B. , 2012, Trends in molecular medicine.

[325]  Haitao Luo,et al.  Kaempferol inhibits VEGF expression and in vitro angiogenesis through a novel ERK-NFκB-cMyc-p21 pathway. , 2012, Food chemistry.

[326]  E. Baudin,et al.  Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[327]  Xuan Liu,et al.  Tanshinone II--a inhibits angiogenesis through down regulation of COX-2 in human colorectal cancer. , 2012, Asian Pacific journal of cancer prevention : APJCP.

[328]  W. Curran,et al.  A phase 1b trial of the combination of the antiangiogenic agent sunitinib and radiation therapy for patients with primary and metastatic central nervous system malignancies , 2011, Cancer.

[329]  R. Motzer,et al.  Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial , 2011, The Lancet.

[330]  Stephanie Alexander,et al.  Cancer Invasion and the Microenvironment: Plasticity and Reciprocity , 2011, Cell.

[331]  P. Park,et al.  Phase II study of neoadjuvant bevacizumab and radiotherapy for resectable soft tissue sarcomas. , 2011, International journal of radiation oncology, biology, physics.

[332]  R. V. van Klaveren,et al.  A double-blind, randomised, placebo-controlled phase III intergroup study of gefitinib in patients with advanced NSCLC, non-progressing after first line platinum-based chemotherapy (EORTC 08021/ILCP 01/03). , 2011, European journal of cancer.

[333]  T. Meyer,et al.  Role of everolimus in pancreatic neuroendocrine tumors , 2011, Expert review of anticancer therapy.

[334]  G. Dranoff,et al.  Anti-angiogenesis immunotherapy , 2011, Human vaccines.

[335]  G. Christofori,et al.  Angiopoietin-1 and -2 exert antagonistic functions in tumor angiogenesis, yet both induce lymphangiogenesis. , 2011, Cancer research.

[336]  Jun Ma,et al.  Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. , 2011, The Lancet. Oncology.

[337]  D. Zopf,et al.  Regorafenib (BAY 73‐4506): A new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity , 2011, International journal of cancer.

[338]  E. D. de Vries,et al.  Everolimus for advanced pancreatic neuroendocrine tumors. , 2011, The New England journal of medicine.

[339]  Y. Bang,et al.  Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. , 2011, The New England journal of medicine.

[340]  Jin Li,et al.  Safety and pharmacokinetics of novel selective vascular endothelial growth factor receptor-2 inhibitor YN968D1 in patients with advanced malignancies , 2010, BMC Cancer.

[341]  O. Volpert,et al.  Sonic hedgehog induces angiogenesis via Rho kinase-dependent signaling in endothelial cells. , 2010, Journal of molecular and cellular cardiology.

[342]  Marie-José Goumans,et al.  Signaling by members of the TGF-beta family in vascular morphogenesis and disease. , 2010, Trends in cell biology.

[343]  M. Casey,et al.  Lapatinib Plus Capecitabine in Women with HER-2–Positive Advanced Breast Cancer: Final Survival Analysis of a Phase III Randomized Trial , 2010, The oncologist.

[344]  N. Ferrara,et al.  Targeting the tumour vasculature: insights from physiological angiogenesis , 2010, Nature Reviews Cancer.

[345]  M. Molski,et al.  A theoretical study of the structure-radical scavenging activity of trans-resveratrol analogues and cis-resveratrol in gas phase and water environment. , 2010, European journal of medicinal chemistry.

[346]  Mingyao Liu,et al.  Celastrol suppresses angiogenesis-mediated tumor growth through inhibition of AKT/mammalian target of rapamycin pathway. , 2010, Cancer research.

[347]  N. Turner,et al.  Fibroblast growth factor signalling: from development to cancer , 2010, Nature Reviews Cancer.

[348]  T. Gauler,et al.  Erlotinib 150 mg daily plus chemotherapy in advanced pancreatic cancer: an interim safety analysis of a multicenter, randomized, cross-over phase III trial of the ‘Arbeitsgemeinschaft Internistische Onkologie’ , 2010, Anti-cancer drugs.

[349]  D. Pei,et al.  Oncolytic adenovirus expressing interleukin-18 induces significant antitumor effects against melanoma in mice through inhibition of angiogenesis , 2010, Cancer Gene Therapy.

[350]  Saeed Sadeghi,et al.  Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[351]  P. E. Van den Steen,et al.  Neutrophil MMP-9 Proenzyme, Unencumbered by TIMP-1, Undergoes Efficient Activation in Vivo and Catalytically Induces Angiogenesis via a Basic Fibroblast Growth Factor (FGF-2)/FGFR-2 Pathway* , 2009, The Journal of Biological Chemistry.

[352]  Young-Kwang Yoon,et al.  Lapatinib, a Dual EGFR and HER2 Tyrosine Kinase Inhibitor, Downregulates Thymidylate Synthase by Inhibiting the Nuclear Translocation of EGFR and HER2 , 2009, PloS one.

[353]  D. Bonnefont-Rousselot,et al.  Simple spectrophotometric assessment of the trans-/cis-resveratrol ratio in aqueous solutions. , 2009, Analytica chimica acta.

[354]  Donald J. Johann,et al.  Cancer and the tumor microenvironment: a review of an essential relationship , 2009, Cancer Chemotherapy and Pharmacology.

[355]  P. O'Connor,et al.  Nonclinical Antiangiogenesis and Antitumor Activities of Axitinib (AG-013736), an Oral, Potent, and Selective Inhibitor of Vascular Endothelial Growth Factor Receptor Tyrosine Kinases 1, 2, 3 , 2008, Clinical Cancer Research.

[356]  I. Merfort,et al.  Anti-carcinogenic Effects of the Flavonoid Luteolin , 2008, Molecules.

[357]  R. Motzer,et al.  Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial , 2008, The Lancet.

[358]  W. Sommergruber,et al.  BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy. , 2008, Cancer research.

[359]  C. Hughes.  Endothelial–stromal interactions in angiogenesis , 2008, Current opinion in hematology.

[360]  Yuji Yamamoto,et al.  E7080, a novel inhibitor that targets multiple kinases, has potent antitumor activities against stem cell factor producing human small cell lung cancer H146, based on angiogenesis inhibition , 2008, International journal of cancer.

[361]  G. Sonpavde,et al.  Pazopanib: A novel multitargeted tyrosine kinase inhibitor , 2007, Current oncology reports.

[362]  M. Dewhirst,et al.  Systemic overexpression of angiopoietin-2 promotes tumor microvessel regression and inhibits angiogenesis and tumor growth. , 2007, Cancer research.

[363]  Apurva A Desai,et al.  Sorafenib in advanced clear-cell renal-cell carcinoma. , 2007, The New England journal of medicine.

[364]  R. Figlin,et al.  Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. , 2007, The New England journal of medicine.

[365]  Xin Huang,et al.  Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial , 2006, The Lancet.

[366]  Yasunari Fujiwara,et al.  KRN951, a highly potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, has antitumor activities and affects functional vascular properties. , 2006, Cancer research.

[367]  S. Wilhelm,et al.  Sorafenib (BAY 43-9006, Nexavar), a dual-action inhibitor that targets RAF/MEK/ERK pathway in tumor cells and tyrosine kinases VEGFR/PDGFR in tumor vasculature. , 2006, Methods in enzymology.

[368]  S. Barry,et al.  AZD2171: a highly potent, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for the treatment of cancer. , 2005, Cancer research.

[369]  K. Alitalo,et al.  VEGF guides angiogenic sprouting utilizing endothelial tip cell filopodia , 2003, The Journal of cell biology.

[370]  M. Sliwkowski,et al.  Preclinical studies with Erlotinib (Tarceva). , 2003, Seminars in oncology.

[371]  P. Carmeliet.  Angiogenesis in health and disease , 2003, Nature Medicine.

[372]  Juthamas Sukbuntherng,et al.  In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[373]  G. Fontanini,et al.  ZD6474, an orally available inhibitor of KDR tyrosine kinase activity, efficiently blocks oncogenic RET kinases. , 2002, Cancer research.

[374]  J. Becker,et al.  A DNA vaccine against VEGF receptor 2 prevents effective angiogenesis and inhibits tumor growth , 2002, Nature Network Boston.

[375]  G. Tortora,et al.  Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitor. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[376]  I. Stamenkovic,et al.  Cell surface-localized matrix metalloproteinase-9 proteolytically activates TGF-beta and promotes tumor invasion and angiogenesis. , 2000, Genes & development.

[377]  W. Denny,et al.  Specific, irreversible inactivation of the epidermal growth factor receptor and erbB2, by a new class of tyrosine kinase inhibitor. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[378]  C. Koboldt,et al.  Specific COX-2 inhibitors: from bench to bedside , 1998 .

[379]  B. C. Patterson,et al.  Angiostatin-converting Enzyme Activities of Human Matrilysin (MMP-7) and Gelatinase B/Type IV Collagenase (MMP-9)* , 1997, The Journal of Biological Chemistry.

[380]  J. Folkman.  Tumor angiogenesis: therapeutic implications. , 1971, The New England journal of medicine.